

Special Issue

Advances in Pheochromocytoma and Paraganglioma

Message from the Guest Editor

Pheochromocytoma and Paraganglioma (PPGL) are rare neuroendocrine characterized by catecholamine secretion which are responsible for alterations in basically all organ systems. Undiagnosed and untreated PPGLs are associated with high morbidity and mortality. Recent years lead to significant progress in the genetics, pathogenesis, and metabolomics of PPGLs, which, in turn, allows for the development of novel diagnostic and therapeutic methods. The diagnosis and treatment of metastatic PPGL represents a major health concern and is the main focus of researchers.

The journal *Biomedicines* is launching the Special Issue on Advances in Pheochromocytoma and Paraganglioma. Reviews or original articles dealing with the genetic, biochemical, and molecular aspects associated with PPGL, pathogenesis in experimental models and humans, as well as articles providing an up-to-date overview of the use of circulating/tissue biomarkers in early diagnosis and management of PPGL and metastatic disease are particularly welcome. We warmly invite you to submit articles reporting on evidence and expectations from innovative and personalized treatments.

Guest Editor

Dr. Ivana Jochmanová

1st Department of Internal Medicine, Faculty of Medicine, Pavol Jozef Šafárik University in Košice and Teaching Hospital of Louis Pasteur, Košice, Slovakia

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/104280

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).